6-Mercaptopurine (Synonyms: 巯嘌呤; Mercaptopurine; 6-MP)

目录号: HY-13677 纯度: 99.93%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

6-Mercaptopurine 是一种嘌呤类似物，是内源性嘌呤的拮抗剂且已被广泛用作抗白血病药物和免疫抑制药物。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

6-Mercaptopurine Chemical Structure

CAS No. : 50-44-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
50 mg	￥450	In-stock
100 mg	￥650	In-stock
500 mg	￥990	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of 6-Mercaptopurine:

MCE 顾客使用本产品发表的 10 篇科研文献

: 6-Mercaptopurine purchased from MCE. Usage Cited in: Nat Commun. 2022 Nov 17;13(1):7031. [Abstract]; 6-Mercaptopurine (6-MP; 300 µM; pretreatment for 2 h) significantly inhibits EcSTH-induced phosphorylation of AMPK and ACC1 in HeLa^{Tet-on EcSTH} and MDA-MB-231^{Tet-on EcSTH} cells.

6-Mercaptopurine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.

IC₅₀ & Target

endogenous purines^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	47 μM Compound: C2	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
A549	IC₅₀	47 μM Compound: C2	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
A549	IC₅₀	47 μM Compound: 6-mercaptopurine	Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
A549	IC₅₀	49.3 μM Compound: 6-mercaptopurine	Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
A549	IC₅₀	49.4 μM Compound: C2	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
ASPC1	IC₅₀	2.45 μM Compound: 6-MP	Cytotoxicity against human Aspc-1 cells by crystal violet staining Cytotoxicity against human Aspc-1 cells by crystal violet staining	[PMID: 20930123]
B16	IC₅₀	0.8 μg/mL Compound: 6-MP	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 7807120]
C6	IC₅₀	30.2 μg/mL Compound: 6-MP	Cytotoxicity against rat C6 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 11087619]
CCRF-CEM	CC₅₀	1 μM Compound: 6MP	Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 21741130]
CCRF-CEM	IC₅₀	1 μM Compound: 6MP	Antiproliferative activity against human CCRF-CEM cells by MTT assay Antiproliferative activity against human CCRF-CEM cells by MTT assay	[PMID: 17254669]
CCRF-SB	IC₅₀	1 μM Compound: 6MP	Antiproliferative activity against human CCRF-SB cells by MTT assay Antiproliferative activity against human CCRF-SB cells by MTT assay	[PMID: 17254669]
CCRF-SB	CC₅₀	1.1 μM Compound: 6MP	Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 21741130]
COLO357	IC₅₀	6.12 μM Compound: 6-MP	Cytotoxicity against human Colo-357 cells by crystal violet staining Cytotoxicity against human Colo-357 cells by crystal violet staining	[PMID: 20930123]
CRL-7065 cell line	IC₅₀	> 100 μM Compound: 6MP	Antiproliferative activity against human CRL7065 cells by MTT assay Antiproliferative activity against human CRL7065 cells by MTT assay	[PMID: 17254669]
DAN-G	IC₅₀	4.06 μM Compound: 6-MP	Cytotoxicity against human DAN-G cells by crystal violet staining Cytotoxicity against human DAN-G cells by crystal violet staining	[PMID: 20930123]
Daudi	IC₅₀	> 200 μM Compound: 6-MP	Antiproliferative activity against human Daudi cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human Daudi cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
DU-145	CC₅₀	2 μM Compound: 6MP	Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay	[PMID: 21741130]
DU-145	IC₅₀	2 μM Compound: 6MP	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	[PMID: 17254669]
HEK293	IC₅₀	0.007 μM Compound: 6-MP	Antiproliferative activity against HEK293 cells assessed as reduction of cell growth after 72 hrs by MTT method Antiproliferative activity against HEK293 cells assessed as reduction of cell growth after 72 hrs by MTT method	[PMID: 10757708]
HEK293	IC₅₀	0.007 μM Compound: 6-MP	Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay	[PMID: 16643040]
HEK293	IC₅₀	0.007 μM Compound: 6-MP	Antiproliferative activity against human HEK293 cells after 72 hrs by MTT conversion assay Antiproliferative activity against human HEK293 cells after 72 hrs by MTT conversion assay	[PMID: 18442289]
HEK293	IC₅₀	0.007 μM Compound: 6-MP	Antiproliferative activity against HEK293 cells after 72 hrs by MTT conversion assay Antiproliferative activity against HEK293 cells after 72 hrs by MTT conversion assay	[PMID: 16989528]
HEK293	IC₅₀	7.1 x 10^-7 mg/mL Compound: 6-mercaptopurine	Cytotoxicity against HEK293 cells by rapid colorimetric assay Cytotoxicity against HEK293 cells by rapid colorimetric assay	[PMID: 19133758]
HeLa	IC₅₀	> 200 μM Compound: 6-MP	Antiproliferative activity against human HeLa cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human HeLa cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
HeLa	ED₅₀	0.1 μg/mL Compound: 6-Mercaptopurine	Cytostatic activity against human HeLa cells assessed as growth inhibition after 72 hrs by colorimetric method Cytostatic activity against human HeLa cells assessed as growth inhibition after 72 hrs by colorimetric method	[PMID: 671455]
HeLa	ED₅₀	0.1 μg/mL Compound: 6-mercaptopurine	In vitro cytostatic activity against human HeLa cells assessed as cell growth after 72 hrs by colorimetric method In vitro cytostatic activity against human HeLa cells assessed as cell growth after 72 hrs by colorimetric method	[PMID: 458800]
HeLa	ED₅₀	0.1 μg/mL Compound: 6-mercaptopurine	Cytostatic activity against human HeLa cells after 72 hrs by FCR-based colorimetric method Cytostatic activity against human HeLa cells after 72 hrs by FCR-based colorimetric method	[PMID: 448680]
HeLa	IC₅₀	2.9 μM Compound: C2	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
HeLa	IC₅₀	2.9 μM Compound: C2	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
HeLa	IC₅₀	2.9 μM Compound: 6-mercaptopurine	Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
HeLa	IC₅₀	4.1 μM Compound: C2	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
HeLa	IC₅₀	4.1 μM Compound: 6-mercaptopurine	Cytotoxicity against human HeLa cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
HEp-2	IC₅₀	317.8 μM Compound: 6-mercaptopurine	Cytotoxicity against human Hep2 cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
HEp-2	IC₅₀	431 μM Compound: 6-mercaptopurine	Cytotoxicity against human Hep2 cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
HepG2	CC₅₀	8 μM Compound: 6MP	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 21741130]
HepG2	IC₅₀	8 μM Compound: 6MP	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 17254669]
HT-29	IC₅₀	> 200 μM Compound: 6-MP	Antiproliferative activity against multidrug-resistant human HT-29 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against multidrug-resistant human HT-29 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
HT-29	IC₅₀	0.87 μg/mL Compound: 6-MP	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 7807120]
IGR-1	IC₅₀	1.1 μg/mL Compound: 6-MP	Antiproliferative activity against human IGR-1 cells after 72 hrs by MTT assay Antiproliferative activity against human IGR-1 cells after 72 hrs by MTT assay	[PMID: 9358643]
IGR-1	IC₅₀	12.3 μg/mL Compound: 6-MP	Antiproliferative activity against human IGR-1 cells after 48 hrs by MTT assay Antiproliferative activity against human IGR-1 cells after 48 hrs by MTT assay	[PMID: 9358643]
IGR-1	IC₅₀	51.7 μg/mL Compound: 6-MP	Cytotoxicity against human IGR-1 cells after 24 hrs by MTT assay Cytotoxicity against human IGR-1 cells after 24 hrs by MTT assay	[PMID: 9358643]
J774	IC₅₀	0.003 μM Compound: 6-MP	Antiproliferative activity against mouse J774 cells assessed as reduction of cell growth after 72 hrs by MTT method Antiproliferative activity against mouse J774 cells assessed as reduction of cell growth after 72 hrs by MTT method	[PMID: 10757708]
J774	IC₅₀	0.5 μg/mL Compound: 6-MP	Antiproliferative activity against mouse J774 cells after 72 hrs by MTT assay Antiproliferative activity against mouse J774 cells after 72 hrs by MTT assay	[PMID: 9358643]
J774	IC₅₀	3.6 μg/mL Compound: 6-MP	Antiproliferative activity against mouse J774 cells after 48 hrs by MTT assay Antiproliferative activity against mouse J774 cells after 48 hrs by MTT assay	[PMID: 9358643]
J774	IC₅₀	61 μg/mL Compound: 6-MP	Cytotoxicity against mouse J774 cells after 24 hrs by MTT assay Cytotoxicity against mouse J774 cells after 24 hrs by MTT assay	[PMID: 9358643]
J774.A1	IC₅₀	0.003 μM Compound: 6-MP	Antiproliferative activity against mouse J774.A1 cells after 3 days by MTT conversion assay Antiproliferative activity against mouse J774.A1 cells after 3 days by MTT conversion assay	[PMID: 16643040]
J774.A1	IC₅₀	0.003 μM Compound: 6-MP	Antiproliferative activity against mouse J774.A1 cells after 72 hrs by MTT conversion assay Antiproliferative activity against mouse J774.A1 cells after 72 hrs by MTT conversion assay	[PMID: 18442289]
J774.A1	IC₅₀	0.003 μM Compound: 6-MP	Antiproliferative activity against mouse J774A1 cells after 72 hrs by MTT conversion assay Antiproliferative activity against mouse J774A1 cells after 72 hrs by MTT conversion assay	[PMID: 16989528]
J774.A1	IC₅₀	5.1 ng/mL Compound: 6-mercaptopurine	Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay	[PMID: 19133758]
Jurkat	IC₅₀	> 200 μM Compound: 6-MP	Antiproliferative activity against human Jurkat cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human Jurkat cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
K562	IC₅₀	> 10 μg/mL Compound: 6-MP	Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay	[PMID: 12617912]
K562	IC₅₀	0.4 μg/mL Compound: 6-mercaptopurine	Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 48 h Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 48 h	[PMID: 11844673]
K562	IC₅₀	0.6 μg/mL Compound: 6-MP	Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay	[PMID: 12617912]
K562	IC₅₀	8.5 μg/mL Compound: 6-mercaptopurine	Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 5 h Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 5 h	[PMID: 11844673]
KB	ED₅₀	0.1 μg/mL Compound: 6-Mercaptopurine	Cytostatic activity against human KB cells assessed as growth inhibition after 72 hrs by colorimetric method Cytostatic activity against human KB cells assessed as growth inhibition after 72 hrs by colorimetric method	[PMID: 671455]
KB	IC₅₀	0.55 μg/mL Compound: 6-MP	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 7807120]
MCF7	IC₅₀	1.4 μM Compound: C2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	1.4 μM Compound: C2	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
MCF7	IC₅₀	1.4 μM Compound: 6-mercaptopurine	Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
MCF7	IC₅₀	3 μM Compound: 6MP	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 17254669]
MCF7	CC₅₀	3.2 μM Compound: 6MP	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 21741130]
MCF7	IC₅₀	5.8 μM Compound: C2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	5.8 μM Compound: 6-mercaptopurine	Cytotoxicity against human sMCF7 cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human sMCF7 cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
MOLT-4	IC₅₀	50.5 μM Compound: 6-MP	Antiproliferative activity against human MOLT4 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human MOLT4 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
MT4	CC₅₀	0.1 μM Compound: 6MP	Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay	[PMID: 21741130]
MT4	IC₅₀	0.1 μM Compound: 6MP	Antiproliferative activity against human MT4 cells by MTT assay Antiproliferative activity against human MT4 cells by MTT assay	[PMID: 17254669]
P388	IC₅₀	0.26 μg/mL Compound: 6-MP	Cytotoxicity against mouse doxorubicin resistant P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse doxorubicin resistant P388 cells after 72 hrs by MTT assay	[PMID: 7807120]
P388	IC₅₀	0.3 μg/mL Compound: 6-MP	Antiproliferative activity against mouse P388 cells after 72 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 9358643]
P388	IC₅₀	0.7 μg/mL Compound: 6-MP	Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay	[PMID: 7807120]
P388	IC₅₀	2.1 μg/mL Compound: 6-MP	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 9358643]
P388	IC₅₀	37 μg/mL Compound: 6-MP	Cytotoxicity against mouse P388 cells after 24 hrs by MTT assay Cytotoxicity against mouse P388 cells after 24 hrs by MTT assay	[PMID: 9358643]
PANC-1	IC₅₀	6.39 μM Compound: 6-MP	Cytotoxicity against human PANC1 cells by crystal violet staining Cytotoxicity against human PANC1 cells by crystal violet staining	[PMID: 20930123]
PaTu 8988t	IC₅₀	4.09 μM Compound: 6-MP	Cytotoxicity against human Patu-T cells by crystal violet staining Cytotoxicity against human Patu-T cells by crystal violet staining	[PMID: 20930123]
PBMC	IC₅₀	149.5 nM Compound: 6-MP	Inhibition of T cell mitogen-induced blastogenesis in human PBMC after 4 days Inhibition of T cell mitogen-induced blastogenesis in human PBMC after 4 days	[PMID: 18467007]
REH	IC₅₀	2.94 μM Compound: 6TP	Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay	[PMID: 30774864]
S49	EC₅₀	> 1000 μM Compound: 6-MP	Cytotoxicity against HGPRTase-deficient mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay Cytotoxicity against HGPRTase-deficient mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay	[PMID: 221658]
S49	EC₅₀	8 μM Compound: 6-MP	Cytotoxicity against wild type mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay Cytotoxicity against wild type mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay	[PMID: 221658]
SK-MEL-28	CC₅₀	15 μM Compound: 6MP	Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay	[PMID: 21741130]
SK-MEL-28	IC₅₀	15 μM Compound: 6MP	Antiproliferative activity against human SK-MEL-28 cells by MTT assay Antiproliferative activity against human SK-MEL-28 cells by MTT assay	[PMID: 17254669]
SK-MES-1	CC₅₀	58 μM Compound: 6MP	Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay	[PMID: 21741130]
SK-MES-1	IC₅₀	58 μM Compound: 6MP	Antiproliferative activity against human SKMES1 cells by MTT assay Antiproliferative activity against human SKMES1 cells by MTT assay	[PMID: 17254669]
U-937	IC₅₀	> 200 μM Compound: 6-MP	Antiproliferative activity against human U937 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay Antiproliferative activity against human U937 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay	[PMID: 18467007]
Vero	IC₅₀	> 117 μM Compound: C2	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Vero	IC₅₀	118.6 μM Compound: 6-mercaptopurine	Cytotoxicity against african green monkey Vero cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
Vero	IC₅₀	67.5 μM Compound: 6-mercaptopurine	Cytotoxicity against african green monkey Vero cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
Vero	IC₅₀	67.6 μM Compound: C2	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Vero	IC₅₀	67.6 μM Compound: C2	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
WEHI-164	IC₅₀	0.015 μM Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 3 days by MTT conversion assay Antiproliferative activity against mouse WEHI164 cells after 3 days by MTT conversion assay	[PMID: 16643040]
WEHI-164	IC₅₀	0.015 μM Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay	[PMID: 18442289]
WEHI-164	IC₅₀	0.015 μM Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay	[PMID: 16989528]
WEHI-164	IC₅₀	0.017 μM Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells assessed as reduction of cell growth after 72 hrs by MTT method Antiproliferative activity against mouse WEHI164 cells assessed as reduction of cell growth after 72 hrs by MTT method	[PMID: 10757708]
WEHI-164	IC₅₀	1.3 μg/mL Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay Antiproliferative activity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 11430005]
WEHI-164	IC₅₀	1.3 μg/mL Compound: 6-MP	Cytotoxicity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 11087619]
WEHI-164	IC₅₀	2.5 ng/mL Compound: 6-mercaptopurine	Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay	[PMID: 19133758]
WEHI-164	IC₅₀	2.7 μg/mL Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT assay Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT assay	[PMID: 9358643]
WEHI-164	IC₅₀	42 μg/mL Compound: 6-MP	Antiproliferative activity against mouse WEHI164 cells after 48 hrs by MTT assay Antiproliferative activity against mouse WEHI164 cells after 48 hrs by MTT assay	[PMID: 9358643]
WEHI-164	IC₅₀	83 μg/mL Compound: 6-MP	Cytotoxicity against mouse WEHI164 cells after 24 hrs by MTT assay Cytotoxicity against mouse WEHI164 cells after 24 hrs by MTT assay	[PMID: 9358643]
WIL2-NS	CC₅₀	3 μM Compound: 6MP	Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay	[PMID: 21741130]
WIL2-NS	IC₅₀	3 μM Compound: 6MP	Antiproliferative activity against human WIL-2NS cells by MTT assay Antiproliferative activity against human WIL-2NS cells by MTT assay	[PMID: 17254669]

体外研究
(In Vitro)

6-Mercaptopurine hydrate (6-MP) induces NR4A3 transcriptional activity 1.6- to 11-fold (P<0.01) in a dose-responsive manner. It is found that 6-Mercaptopurine hydrate leads to a dose-dependent increase in NR4A3 protein levels. 6-MP treatment increases cell surface GLUT4 in both basal cells 1.8- to 3.6-fold (P<0.01) and insulin-stimulated cells 2.9- to 4.4-fold (P<0.01) over that in controls. It is also found that 6-Mercaptopurine hydrate increases phospho-AS160 significantly in a dose-responsive manner under both basal and insulin-stimulated conditions^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

152.18

Formula

C₅H₄N₄S

CAS 号

50-44-2

性状

固体

颜色

Light yellow to yellow

中文名称

巯嘌呤； 6-巯基嘌呤

结构分类

Others

初始来源

内源性代谢物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 35.71 mg/mL (234.66 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	6.5712 mL	32.8558 mL	65.7117 mL
5 mM	1.3142 mL	6.5712 mL	13.1423 mL
10 mM	0.6571 mL	3.2856 mL	6.5712 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.43 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (16.43 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (16.43 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 3.33 mg/mL (21.88 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.93%

选择批次：

Data Sheet (630 KB) SDS (644 KB)

COA (290 KB) HNMR (246 KB) LCMS (86 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Sahasranaman S, et al. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. [Content Brief]

[2]. Liu Q, et al. 6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3. Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1081-92. [Content Brief]

[3]. Kanemitsu H, et al. 6-Mercaptopurine (6-MP) induces cell cycle arrest and apoptosis of neural progenitor cells in the developing fetal rat brain. Neurotoxicol Teratol. 2009 Mar-Apr;31(2):104-9. [Content Brief]

Kinase Assay ^[2]	L6 myotubes are treated with DMSO control or 6-Mercaptopurine hydrate (6-MP) for 24 h, with the final 3 h of incubation including treatments in serum-free DMEM, and further incubated in the absence or presence of 100 nM insulin for 60 min at 37°C. Then, protein lysates (50 μg) are collected and subjected to SDS-PAGE and immunoblotted with primary antibodies against overnight at 4°C. The proteins are finally quantified by densitometric analysis of scanned films using Image J software^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[2]	Cell viability is measured using Cell Viability Assay. L6 skeletal muscle cells are seeded in 96-well plates at a density of 10,000 cells/well and differentiated into myotubes within 7 days. Cells are treated with different doses of 6-Mercaptopurine hydrate (6-MP) for 24 h before the assay. For analysis of cell viability, plates are equilibrated at room temperature for 30 min; 50 μL of Cell Titer-Glo reagent is added to each well, and plates are mixed for 12 min on an orbital shaker. Luminescence is quantified using a luminometer^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration	Around thirteen-week-old pregnant rats are used in this study. The animals are housed individually in wire-mesh cages in an air-conditioned room (temperature, 23±3°C; humidity, 50±20%; ventilation, 10 times/hour; lighting, 12 h light to12 h dark cycle) and are given pelleted diet and water ad libitum. In the experiment, fifteen pregnant rats are injected i.p. with 50 mg/kg 6-Mercaptopurine hydrate (6-MP) on E13, and three dams each are sacrificed by exsanguination from the abdominal aorta under ether anesthesia at 12, 24, 36, 48, and 72 h. Fetuses are collected from each dam by Caesarean section. As controls, fifteen pregnant rats are injected i.p. with 2.0% methylcellulose solution in distilled water at E13, and three dams are sacrificed at each of the same time-points^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Sahasranaman S, et al. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. [Content Brief] [2]. Liu Q, et al. 6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3. Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1081-92. [Content Brief] [3]. Kanemitsu H, et al. 6-Mercaptopurine (6-MP) induces cell cycle arrest and apoptosis of neural progenitor cells in the developing fetal rat brain. Neurotoxicol Teratol. 2009 Mar-Apr;31(2):104-9. [Content Brief]

6-Mercaptopurine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	6.5712 mL	32.8558 mL	65.7117 mL	164.2792 mL
	5 mM	1.3142 mL	6.5712 mL	13.1423 mL	32.8558 mL
	10 mM	0.6571 mL	3.2856 mL	6.5712 mL	16.4279 mL
	15 mM	0.4381 mL	2.1904 mL	4.3808 mL	10.9519 mL
	20 mM	0.3286 mL	1.6428 mL	3.2856 mL	8.2140 mL
	25 mM	0.2628 mL	1.3142 mL	2.6285 mL	6.5712 mL
	30 mM	0.2190 mL	1.0952 mL	2.1904 mL	5.4760 mL
	40 mM	0.1643 mL	0.8214 mL	1.6428 mL	4.1070 mL
	50 mM	0.1314 mL	0.6571 mL	1.3142 mL	3.2856 mL
	60 mM	0.1095 mL	0.5476 mL	1.0952 mL	2.7380 mL
	80 mM	0.0821 mL	0.4107 mL	0.8214 mL	2.0535 mL
	100 mM	0.0657 mL	0.3286 mL	0.6571 mL	1.6428 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

6-Mercaptopurine50-44-2Mercaptopurine 6-MP巯嘌呤 6-巯基嘌呤Nucleoside Antimetabolite/AnalogAutophagyEndogenous MetaboliteInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

6-Mercaptopurine (Synonyms: 巯嘌呤; Mercaptopurine; 6-MP)

Customer Review

Other Forms of 6-Mercaptopurine:

MCE 顾客使用本产品发表的 10 篇科研文献

6-Mercaptopurine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

6-Mercaptopurine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

6-Mercaptopurine (Synonyms: 巯嘌呤; Mercaptopurine; 6-MP)

Customer Review

Other Forms of 6-Mercaptopurine:

6-Mercaptopurine 相关抗体

MCE 顾客使用本产品发表的 10 篇科研文献

6-Mercaptopurine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

6-Mercaptopurine 相关抗体:

摩尔计算器

稀释计算器

6-Mercaptopurine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z